Renal Cell Therapy and Beyond
dc.contributor.author | Song, Joon ho | en_US |
dc.contributor.author | Humes, H. David | en_US |
dc.date.accessioned | 2011-01-13T19:42:00Z | |
dc.date.available | 2011-01-13T19:42:00Z | |
dc.date.issued | 2009-11 | en_US |
dc.identifier.citation | Song, Joon ho; Humes, H. david; (2009). "Renal Cell Therapy and Beyond." Seminars in Dialysis 22(6): 603-609. <http://hdl.handle.net/2027.42/78659> | en_US |
dc.identifier.issn | 0894-0959 | en_US |
dc.identifier.issn | 1525-139X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78659 | |
dc.description.abstract | Although current dialysis techniques have transformed acute and chronic renal failure from uniformly fatal clinical disorders into treatable diseases, these therapies replace only the water and solute clearance function of the kidney and have reached a point where little further therapeutic improvement can be anticipated. In addition to their metabolic and endocrine functions, renal tubule cells presumably play an important role in the systemic inflammatory balance by participating in the complex and dynamic network of leukocyte action and pro- and anti-inflammatory cytokines. Loss of this function may result in a propensity to develop systemic inflammatory response syndrome (SIRS), multiorgan dysfunction, and a high risk of death in acute kidney injury (AKI), and may relate to chronic inflammatory state in end-stage renal disease (ESRD). A renal tubule cell assist device (RAD) containing animal or human renal tubule cells has been recently developed with the purpose of integrating the functions of tubule cells with the filtration function of current dialysis to offer a more complete renal replacement therapy. The viability and functionality of this device were confirmed in in vitro experiments and large animal studies, and recently the RAD’s clinical therapeutic benefit was demonstrated with a series of FDA-approved human trials. Another novel synthetic membrane extracorporeal device that binds and inhibits circulating leukocytes has been developed with the purpose of reducing microvascular damage promoted primarily via activated circulating leukocytes in AKI and SIRS. This device, called a selective cytopheretic inhibitory device, mimics immunomodulation and duplicates RAD efficiency in preliminary studies. Both devices may become comprehensive treatments, replacing full renal function and correcting inflammatory imbalance in patients with acute and chronic renal disorders. | en_US |
dc.format.extent | 251132 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.title | Renal Cell Therapy and Beyond | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Center for Advanced Medical Education by BK21 Project, Inha University School of Medicine, Incheon, Korea | en_US |
dc.identifier.pmid | 20017829 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78659/1/j.1525-139X.2009.00663.x.pdf | |
dc.identifier.doi | 10.1111/j.1525-139X.2009.00663.x | en_US |
dc.identifier.source | Seminars in Dialysis | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.